Peptide Report
BPC-157 Peptide Report
Catalog report for BPC-157, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.
Current Price$47.00 – $82.00 CAD
Common Uses
People commonly use BPC-157 for recovery-focused routines involving joints, tendons, ligaments, muscle soreness, and digestive wellness, especially when dealing with nagging training or mobility issues.
How It Works
BPC-157 is a synthetic fragment modeled from a gastric protective protein. It is studied for effects on angiogenesis, nitric-oxide signaling, growth-factor pathways, collagen organization, and inflammatory balance in gut and connective-tissue models.
Storage
Powder form: In lyophilized powder form, BPC-157 is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.
Reconstituted: After reconstitution, BPC-157 should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.
Protocol
The full BPC-157 protocol is included below. The standalone protocol page remains available if you want to open it separately.
Open Standalone Protocol
Scope
Preparation examples, syringe conversion, community-reported patterns and human-evidence limitations.
Available strengths: 5 MG and 10 MG
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup |
Diluent |
Concentration |
Unit conversion |
| 5 MG vial – 2.0 mL example |
Add 2.0 mL bacteriostatic water |
2.5 mg/mL |
Each U-100 unit = 25 mcg |
| 10 MG vial – 2.0 mL example |
Add 2.0 mL bacteriostatic water |
5 mg/mL |
Each U-100 unit = 50 mcg |
Syringe Conversion
| Reported amount |
5 MG setup |
10 MG setup |
| 100 mcg |
4 units |
2 units |
| 250 mcg |
10 units |
5 units |
| 500 mcg |
20 units |
10 units |
| 750 mcg |
30 units |
15 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
| Recurring report |
Frequency seen |
Context in reports |
| 250 mcg |
Once daily |
Lower-start and tolerance reports |
| 250 mcg |
Twice daily |
Frequently repeated split pattern |
| 500 mcg |
Once daily |
Frequently repeated daily total |
Observations
- The reviewed discussions most often clustered around 250-500 mcg total per day.
- Both once-daily and split morning/evening administration were reported; no validated human schedule exists.
- Users discussed tendon, muscle, joint and digestive goals, but these anecdotes cannot establish efficacy.
Caveats
- Published human exposure is too limited to characterize BPC-157 safety, pharmacokinetics or an appropriate subcutaneous dose.
- Product identity, purity, sterility and concentration cannot be inferred from online reports, and animal findings do not establish human benefit.